Companies Developing Therapeutics to Fight Covid-19 Will get a $3.2 Billion Injection

Some antiviral pills related to coronavirus will get a $3.2 billion shot in the arm to help accelerate testing and development of therapeutics to combat the Covid-19 virus. This was announced (6/17/21) by the Department of Health and Human Services.

“New antivirals that prevent serious Covid-19 illness and death, especially oral drugs that could be taken at home early in the course of disease, would be powerful tools for battling the pandemic and saving lives,” said President Biden’s, chief medical adviser, Dr. Anthony Fauci.

The $3.2 billion allocated will be from the $1.9 trillion coronavirus relief package Biden signed into law in March. Dr. Fauci said the funding could accelerate clinical trials “already in progress” for some antiviral pills and potentially make candidates available by year’s end. He noted that antiviral pills that patients can use to self-treat at home would serve as an important compliment to vaccinations in preventing severe illness or hospitalization.

There are a number of small and microcap biopharmaceutical companies that are in various stages of exploring new antiviral treatments for Covid and other threats. With Washington’s $3.2 billion as yet unallocated support, perhaps some of these are worth visiting.

CoCrystal Pharma, Inc. (Nasdaq:COCP) is a clinical-stage biotechnology company employing its unique structure-based technologies and Nobel Prize-winning expertise to create and develop first- and best-in-class broad-spectrum antiviral drugs for serious and/or chronic diseases. These technologies are designed to efficiently deliver small-molecule therapeutics that target the viral replication process and are safe, effective and convenient to administer. Cocrystal’s development programs include influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

52 Week Range $0.76-$3.46

CytoDyn, Inc. (OTC:QB CYDY) Inc. is US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. IPIX will hold a webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments .

52 week price range $1.63-$10.01

Avalon GloboCare Corp. (Nasdaq:AVCO) Avalon GloboCare, a leading biotechnology company focusing on cell-based technology and therapeutics, is about to launch clinical trials of its novel blood filtration system to mitigate symptoms of a cytokine storm in COVID-19 patients and a mucosal intranasal spray vaccination against SARS-CoV-2.

52 week price range $0.87- $2.16

Too Many to List

Other companies at various stages of testing development can be found below the article by scrolling down. Click on the tickers for more details on their work and data on the company.

Suggested Reading: